default author photo

Mai Thi Nhu Tran

Nanogen Pharmaceutical Biotechnology JSC

Vietnam

SCHOLARLY PAPERS

1

DOWNLOADS

225

TOTAL CITATIONS

0

Scholarly Papers (1)

1.

Safety and Immunogenicity of Nanocovax, a SARS-CoV-2 Recombinant Spike Protein Vaccine

Number of pages: 70 Posted: 14 Oct 2021
Nanogen Pharmaceutical Biotechnology JSC, Naval Medical University (SMMU), Pasteur Institute Ho Chi Minh City, Vietnam Military Medical University, Nanogen Pharmaceutical Biotechnology JSC, Vietnam Military Medical University, Pasteur Institute Ho Chi Minh City, Vietnam Military Medical University, Vietnam Military Medical University, Pasteur Institute - Department of Disease Control and Prevention, Pasteur Institute Ho Chi Minh City, Nanogen Pharmaceutical Biotechnology JSC, Nanogen Pharmaceutical Biotechnology JSC, Nanogen Pharmaceutical Biotechnology JSC, Nanogen Pharmaceutical Biotechnology JSC, Nanogen Pharmaceutical Biotechnology JSC, Nanogen Pharmaceutical Biotechnology JSC, Nanogen Pharmaceutical Biotechnology JSC, Vietnam Military Medical University, Vietnam Military Medical University, Vietnam Military Medical University, Vietnam Military Medical University, Vietnam Military Medical University, affiliation not provided to SSRN, affiliation not provided to SSRN, Vietnam Military Medical University, Vietnam Military Medical University, Vietnam Military Medical University, Vietnam Military Medical University, Vietnam Military Medical University, Vietnam Military Medical University, Vietnam Military Medical University, Vietnam Military Medical University, Vietnam Military Medical University, Vietnam Military Medical University, Vietnam Military Medical University, Vietnam Military Medical University, Vietnam Military Medical University, Vietnam Military Medical University, Pasteur Institute - Pasteur Institute Ho Chi Minh City, Pasteur Institute - Pasteur Institute Ho Chi Minh City, Pasteur Institute - Pasteur Institute Ho Chi Minh City, Pasteur Institute - Pasteur Institute Ho Chi Minh City, Pasteur Institute - Department of Disease Control and Prevention, Pasteur Institute - Pasteur Institute Ho Chi Minh City, Pasteur Institute - Pasteur Institute Ho Chi Minh City, Pasteur Institute - Pasteur Institute Ho Chi Minh City, Pasteur Institute - Pasteur Institute Ho Chi Minh City, Pasteur Institute - Pasteur Institute Ho Chi Minh City, Pasteur Institute - Pasteur Institute Ho Chi Minh City, Pasteur Institute - Pasteur Institute Ho Chi Minh City, Nanogen Pharmaceutical Biotechnology JSC, Nanogen Pharmaceutical Biotechnology JSC, Nanogen Pharmaceutical Biotechnology JSC, Nanogen Pharmaceutical Biotechnology JSC, Nanogen Pharmaceutical Biotechnology JSC, Nanogen Pharmaceutical Biotechnology JSC, Nanogen Pharmaceutical Biotechnology JSC, Nanogen Pharmaceutical Biotechnology JSC, Nanogen Pharmaceutical Biotechnology JSC and Nanogen Pharmaceutical Biotechnology JSC
Downloads 225 (339,120)

Abstract:

Loading...

SARS-CoV-2, Protein sub-unit vaccine, safety, immunogenicity, phase 1 and 2 clinical trial